Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 32.0% in July

Key Points

• Cellectis S.A. experienced a 32.0% decline in short interest in July, with current short interest totaling 178,800 shares, which represents only 0.4% of its shares outstanding.
• The company reported a loss of ($0.24) EPS for the last quarter, missing expectations, but exceeded revenue forecasts with $18.19 million, against the anticipated $10.07 million.
• Institutional investors hold 63.90% of Cellectis' stock, with significant recent increases from firms like Wells Fargo and UBS Asset Management, reflecting growing investor interest.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 178,800 shares, adecreaseof32.0% from the July 15th total of 263,100 shares. Based on an average daily trading volume, of 143,200 shares, the days-to-cover ratio is currently 1.2 days. Approximately0.4% of the shares of the company are sold short. Approximately0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 143,200 shares, the days-to-cover ratio is currently 1.2 days.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays decreased their price objective on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $4.00.

Institutional Trading of Cellectis

Large investors have recently bought and sold shares of the business. OLD Mission Capital LLC acquired a new stake in Cellectis in the first quarter valued at about $31,000. Wells Fargo & Company MN boosted its stake in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 26,461 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Cellectis during the fourth quarter valued at about $962,000. Finally, Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares in the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Price Performance

NASDAQ:CLLS traded down $0.15 during trading hours on Monday, hitting $2.70. The company's stock had a trading volume of 51,606 shares, compared to its average volume of 225,292. The stock has a fifty day simple moving average of $2.13 and a 200-day simple moving average of $1.66. The company has a market capitalization of $150.08 million, a P/E ratio of -3.29 and a beta of 3.03. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.38 and a quick ratio of 1.38. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.24.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The business had revenue of $18.19 million during the quarter, compared to analyst estimates of $10.07 million. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. On average, analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.